Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2010. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific insider trading notification and does not contain financial performance data.
Material Changes
The only material change disclosed is a reduction in shareholding by a connected person:
- Mr. M Dunoyer sold 15,248 Ordinary shares on August 5, 2010.
- The transaction price was £11.33 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to the requirements of Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the notification of the share sale.
Investor Verification Checklist
- Verify the total shareholding of Mr. M Dunoyer following the sale of 15,248 shares.
- Confirm the market price of GSK Ordinary shares on August 5, 2010, to contextualize the £11.33 transaction price.
- Review subsequent filings to determine if this transaction was part of a broader divestment plan by management.